Evidence map›Paper›PMID 16885396›Full record

ReviewAmerican journal of physiology. Cell physiology2006

Statin-induced apoptosis and skeletal myopathy.

Amie J Dirks, Kimberly M Jones

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in American journal of physiology. Cell physiology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06841536 (Combined Effects of Statins and Exercise on Physiological Health Markers and Quality of Life in Patients With Dyslipidaemia), which is not on this map. Cited by 79 papers.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed
15.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06841536 nacompletedstarted 2025, after this paper: background citation

Combined Effects of Statins and Exercise on Physiological Health Markers and Quality of Life in Patients With Dyslipidaemia

Ran2025Enrolled120Registered outcomes61Posted comparisons0ConditionsDyslipidemiasArmsAtorvastatin 80mg, Exercise
Open the trial in the graph
3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 243 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Evidence for metabolic aberrations in asymptomatic persons with type 2 diabetes after initiation of simvastatin therapy.Translational research : the journal of laboratory and clinical medicine · 2015
    Trial
  5. Simvastatin impairs exercise training adaptations.Journal of the American College of Cardiology · 2013 · on this map
    Trial
  6. Impact ofBiomedicines · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Focal myositis: a literature review of clinical and immunopathological aspects.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2024
    Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Statins Neuromuscular Adverse Effects.International journal of molecular sciences · 2022
    Review
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Amie J DirksWingate University School of Pharmacy, Wingate, North Carolina 28174, USA. adirks@wingate.edu
Kimberly M Jones
Wingate University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Over 100 million prescriptions were filled for statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) in 2004. Statins were originally developed to lower plasma cholesterol in patients with hypercholesterolemia and are the most effective drugs on the market in doing so. Because of the discovered pleiotropic effects of statins, the use has expanded to the treatment of many other conditions, including ventricular arrythmias, idiopathic dilated cardiomyopathy, cancer, osteoporosis, and diabetes. The elderly population is growing. Therefore, it is estimated that the number of statin users will also increase. Fortunately, the use of statins is relatively safe with few side effects. Myopathy is the most common side effect with symptoms ranging from fatigue, weakness, and pain to symptoms associated with rhabdomyolysis which is a life-threatening condition. The development of statin-induced rhabdomyolysis is rare occurring in approximately 0.1% of patients; however, the occurrence of less severe symptoms is underreported and may be 1-5% or more. Physical exercise appears to increase the likelihood for the development of myopathy in patients taking statins. It is thought that as many as 25% of statin users who exercise may experience muscle fatigue, weakness, aches, and cramping due to statin therapy and potentially dismissed by the patient and physician. The mechanisms causing statin-induced myopathy have not been elucidated; however, research efforts suggest that apoptosis of myofibers may contribute. The mitochondrion is considered a regulatory center of apoptosis, and therefore its role in the induction of apoptosis will be discussed as well as the mechanism of statin-induced apoptosis and myopathy.

Indexed as

Muscle, SkeletalAnticholesteremic AgentsApoptosisHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaMitochondriaMuscular DiseasesAnticholesteremic AgentsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID16885396
OpenAlexW2143607032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.